BioReference Laboratories

BioReference Laboratories (BRL) operates as a cornerstone of OPKO Health's diagnostics segment, providing high-complexity and esoteric laboratory services that drive clinical decision-making. Its strategy focuses on integrating innovative tests like the 4Kscore for prostate cancer into its broad service menu, capitalizing on the shift towards personalized medicine. While facing industry headwinds from pricing pressure, BRL differentiates itself through its specialized capabilities in genomics and a national service platform, aiming to grow through expanded test utilization and strategic alignment with OPKO's broader biopharmaceutical efforts.

A comprehensive clinical laboratory platform utilizing next-generation sequencing (NGS), PCR, FISH, microarray, and mass spectrometry, supported by proprietary bioinformatics and IT systems for test analysis, data interpretation, and physician reporting.

Competes directly with giants Quest Diagnostics and LabCorp on scale, while facing pressure from hospital insourcing and niche specialty labs in high-complexity testing. Its differentiation strategy relies on esoteric testing expertise and proprietary OPKO diagnostic assets.